Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.59 |
| ▸ | JAK2 | O60674 | 5/20 | 0.55 |
| ▸ | SMG1 | Q96Q15 | 7/20 | 0.55 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.54 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.54 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434273 | 0.89 | TBK1 (0.61) | TBK1ZAP70MYLK4STK17ACLK4 | |
| SCHEMBL16492351 | 0.88 | TBK1 (0.64) | TBK1JAK2SMG1ZAP70MYLK4 | |
| SCHEMBL13279671 | 0.84 | TBK1 (0.69) | TBK1IKBKE | |
| SCHEMBL13280396 | 0.83 | TBK1 (0.70) | TBK1JAK2IKBKE | |
| SCHEMBL435393 | 0.83 | TBK1 (0.66) | TBK1JAK2MYLK4STK17AJAK3 | |
| SCHEMBL15302199 | 0.82 | JAK2 (0.59) | TBK1JAK2JAK3IKBKEJAK1 | |
| SCHEMBL433158 | 0.82 | TBK1 (0.62) | TBK1JAK2SMG1IKBKECDK1 | |
| SCHEMBL435104 | 0.82 | TBK1 (0.60) | TBK1JAK2ZAP70MYLK4STK17A | |
| SCHEMBL15301604 | 0.82 | TBK1 (0.60) | TBK1JAK2ZAP70MYLK4STK17A | |
| SCHEMBL13279503 | 0.81 | JAK2 (0.64) | TBK1JAK2SMG1ZAP70JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595964-B1 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LTD (GB) | 2015-04-29 | — | — | EP | claimed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | claimed |
| EP-2595964-B1 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHUK, IKBKE, TBKBP1 | TBK1 10/4885JAK2 629/4885SMG1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.